Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2026 02:00 ET | Source: Reset Health

Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota

LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the Company”), the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a...
February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
February 06, 2026 05:00 ET | Source: Visiongain

Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management

The global Anti-obesity Drugs market is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036.
February 04, 2026 16:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
January 28, 2026 07:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
January 23, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...
January 22, 2026 05:00 ET | Source: Resalis Therapeutics SRL

Resalis Therapeutics Appoints Sandor Batkai as Medical Director

Torino, Italy, January 22 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment of Sandor Batkai, MD, PhD, as Medical Director. Dr....
January 15, 2026 03:26 ET | Source: Digbi Health

Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs

MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Digbi Health, the national leader in Precision Biology–based chronic care, today announced peer-reviewed, actuarially validated significant...
January 12, 2026 08:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Kailera announced the first participants randomized in the global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide (KAI-9531).
January 08, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...